ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Aminolevulinic Acid

Also written as “Aminolevulinic Acid (ALA)”, “5 Aminolevulinic Acid” and “PD P 506 A”.

Its studies are mostly in Keratosis, Actinic · Glioma · Glioblastoma · Breast Neoplasms · Malaria, led by 10 companies.

Drug pageAminolevulinic Acid: every studyMany companies study it; this page follows only the 22 they lead. All 114 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since May 7, 201422 company-led studies, 3 open or runningNext primary completion: Oct 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sun Pharmaceutical Industries100 open or runningphase 3since May 7, 2014Jun 24, 2008none ahead
Alpheus Medicalits history only21 open or runningphase 1since May 2, 2022May 2, 2022Oct 30, 2027phase 1 · NCT07862647
medacits history only20 open or runningphase 3since Oct 18, 2005Oct 18, 2005none ahead
photonamic GmbH & Co. KGits history only20 open or runningphase 2since Jul 11, 2018Jul 11, 2018none ahead
Hemerion Therapeuticsits history only11 open or runningphase 2since Feb 8, 2023Feb 8, 2023none ahead
Lee's Pharmaceuticalits history only11 open or runningphase 3since Nov 27, 2023Nov 27, 2023Dec 2027phase 3 · NCT06160492
Neopharma Japanits history only10 open or runningphase 2since Jul 12, 2019Jul 12, 2019none ahead
Nobelpharmaits history only10 open or runningphase 3since Jul 16, 2010Jul 16, 2010none ahead
SBI ALApharma Canadaits history only10 open or runningphase 3since Mar 22, 2021Mar 22, 2021none ahead
Shanghai Fudan-Zhangjiang Bio-Pharmaceuticalits history only10 open or runningphase 3since May 12, 2024May 12, 2024none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sun Pharmaceutical Industries only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 24, 2008First study: phase 2 study in Acne VulgarisFirst studyNCT00706433 · 266 enrolled · United States
  2. Mar 18, 2009Phase 2 study in Keratosis, ActinicNCT00865878 · 6 enrolled · United States
  3. Oct 21, 2011Phase 2 study in Keratosis, ActinicNCT01458587 · 70 enrolled · United States
  4. Nov 15, 2011Phase 2 study in Keratosis, ActinicNCT01475955 · 235 enrolled · United States
  5. May 7, 2014Phase 3 study in Keratosis, ActinicNCT02137785 · 269 enrolled · United States
  6. Sep 10, 2014Phase 2 study in Keratosis, ActinicNCT02239679 · 166 enrolled · United States
  7. Oct 30, 2014Phase 2 study in Keratosis, ActinicNCT02281136 · 29 enrolled · United States
  8. Dec 7, 20152 phase 2 studies in Keratosis, ActinicNCT02628236, NCT02632110
  9. Dec 9, 2015Named aminolevulinic acidINNProposed as its International Nonproprietary Name in WHO's List 114
  10. Jan 13, 2017Phase 3 study in Keratosis, ActinicNCT03024060 · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 Sun Pharmaceutical Industries leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03024060Keratosis, Actinic · United States3WithdrawnSep 20170
NCT02632110Keratosis, Actinic · United States2CompletedSep 12, 2016137
NCT02628236Keratosis, Actinic · United States2CompletedMay 201614
NCT02281136Keratosis, Actinic · United States2CompletedApr 201529
NCT02239679Keratosis, Actinic · United States2CompletedJul 2016166
NCT02137785Keratosis, Actinic · United States3CompletedMar 2015269
NCT01475955Keratosis, Actinic · United States2CompletedNov 2012235
NCT01458587Keratosis, Actinic · United States2CompletedJul 201270
NCT00865878Keratosis, Actinic · United States2TerminatedSep 20116
NCT00706433Acne Vulgaris · United States2CompletedJul 2008266

How it is read

Names in the registry

  • “Aminolevulinic Acid (ALA)”, 3 entries
  • “5 Aminolevulinic Acid”, 2 entries
  • “PD P 506 A”, 2 entries
  • “Aminolevulinic Acid”, 2 entries
  • “ALA”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.